Early Treatment of Children with Bilateral Amblyopia Essential, According to Multisite Study
New study published in American Journal of Ophthalmology
Philadelphia, October 1, 2007 - When a child is farsighted or has astigmatism or has both conditions in both eyes, bilateral amblyopia may develop. In contrast to single-eye amblyopia or "lazy eye," where one eye presents an unclear image to the brain, bilateral amblyopia affects both eyes and is less common. In an article published in the October issue of the American Journal of Ophthalmology, researchers report that this condition can be successfully treated with corrective lenses, particularly when diagnosed and treated early. Left untreated, bilateral amblyopia may result in permanent visual disability.
The Pediatric Eye Disease Investigator Group (PEDIG) conducted a study of 113 children between 3 and 9 years-old with bilateral refractive amblyopia, who were treated with glasses and followed prospectively at 27 community- and university-based sites. After one year, visual acuity measured with both eyes open had improved an average of about 4 lines on the traditional Snellen eye chart. Average visual acuity improved from 20/63 to 20/25, and most children (74%) reached 20/25 or better. Those children who started with visual acuity of 20/100 or worse showed the greatest improvement, averaging 6.3 lines after one year.
"This study shows that glasses are a powerful treatment for bilateral amblyopia in children. When we detect and treat this problem early in life, most children are able to achieve normal vision," said Paul A. Sieving, M.D., Ph.D., Director of the National Eye Institute, one of the Federal government’s National Institutes of Health and the agency that sponsored the study.
"Most ophthalmologists or optometrists will see no more than a few cases of bilateral amblyopia each year, which is not enough to be able to do a large study on this condition. The structure of the Pediatric Eye Disease Investigator Group allows us to enroll children at multiple sites to do large studies of important but relatively uncommon conditions like bilateral amblyopia," said David Wallace, M.D., lead author for the study.
The article is "Treatment of Bilateral Refractive Amblyopia in Children Three to Less Than 10 Years of Age" by David K. Wallace, Danielle l. Chandler, Roy W. Beck, Robert W. Arnold, Darron A. Bacal, Eileen E. Birch, Joost Felius, Marcela Frazier, Jonathan M. Holmes, Darren Hoover, Deborah A. Klimek, Ingryd Lorenzana, Graham E. Quinn, Michael X. Repka, Donny W. Suh, Susanna Tamkins, and the Pediatric Eye Disease Investigator Group. The writing committee and the members of the Pediatric Eye Disease Investigator Group participating in the study are listed at www.AJO.com.
The article appears in the American Journal of Ophthalmology, Volume 144, Issue 4, (October 2007), and is published by Elsevier.
# # #
Full text of the article mentioned above is available upon request. Contact Maureen Hunter at (215) 239-3671 or firstname.lastname@example.org to obtain a copy or to schedule an interview.
About The American Journal Of Ophthalmology
The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented on the Internet at www.AJO.com.
The American Journal of Ophthalmology publishes Original Articles, Brief Reports, Perspectives, Editorials, Abstracts, Correspondence, Book Reports and Announcements. Perspectives, Editorials and Abstracts (from other journals) are published by invitation.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 33,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 215 239 3671